Pfizer Inc (PFE)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
Volatility-scaled: the stop sits about 2× the average daily range (ATR 2.7% of price) below the price, with a 2:1 reward-to-risk target. Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is **none** — these headlines are sector-wide dividend/debt commentary and peer news (BMS, Regeneron) rather than a Pfizer-specific event, with the "stopped talking up this business" item being a soft narrative signal at most. Continuation probability is **low (~20-30%)** for any directional move over the next few weeks, since without a discrete catalyst, PFE is more likely to drift with broad healthcare/macro sentiment than sustain a move. Informational only — not financial advice.
- Moderna Soared 8% on Cancer Data. Friday’s Report Shows Whether It Can Afford the PipelineYahoo · 2026-11-05
- Are Your Dividends Safe? 4 Companies Whose Debt Is Competing With the PayoutYahoo · 2026-11-05
- What Changed In Bristol Myers Squibb's Story?Yahoo · 2026-11-05
- Is Regeneron Stock Riskier Than It Looks?Yahoo · 2026-11-05
- Why Did Pfizer Stop Talking Up This Business?Yahoo · 2026-11-05
Any AI summary is an interpretation of public news, not advice or a price target.